Manage Tickers Link Financial Account

Has my stock been accused of fraud?Join over 160k users who know.

Ticker	Price	Change($)	Change(%)	Shares	Volume	Prev Close	Open	Gain($)	Gain(%)

Ticker	Status	Jurisdiction	Filing Date	CP Start	CP End	CP Loss	Deadline

Ticker	Case Name	Status	CP Start	CP End	Deadline	Settlement Amt

Ticker	Name	Date	Analyst Firm	Up/Down	Target ($)	Rating Change	Rating Current

Agios Pharmaceuticals Says It Is Aware Of The Securities Analyst Report Published On August 4, 2025, Detailing Recent PYRUKYND Data From The U.S. FDA Adverse Event Reporting System; Co. Is Committed To Delivering Safe, Effective Treatments For Patients With Rare Diseases, And Will Continue To Follow Our Established, Rigorous Pharmacovigilance Processes; Separately, On August 4, 2025, The Saudi Food And Drug Authority Announced That It Has Approved PYRUKYND

Author: Benzinga Newsdesk | August 04, 2025 01:53pm

-SEC Filing

Posted In: AGIO